Encapsulated microRNA by gemcitabine prodrug for cancer treatment

Zhang, Hai-Tao; Sun, Jing; Yan, Yongyong; Cui, Shu; Wang, Hao; Wang, Cheng-Han; Qiu, Caian; Chen, Xin; Ding, Jinsong; Qian, Hong-Gang; Wang, Jiancheng; Zhang, Qiang

doi:10.1016/j.jconrel.2019.11.010

Cited by 21 publications

(16 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…M ANY STUDIES HAVE successfully identified miRNAs that are closely related to the invasion and metastasis of HCC in order to establish novel therapeutic approaches and diagnostic criteria . [26][27][28][29] In this report, we identified 13 miRNAs using univariate CPHR analysis and Lasso regression analysis. Next, we identified and validated a 13-miRNA risk signature highly associated with OS of patients with HCC.…”

Section: Discussionmentioning

confidence: 99%

Construction of a 13‐microRNA‐based signature and prognostic nomogram for predicting overall survival in patients with hepatocellular carcinoma

Zheng

Wen

Nie

et al. 2020

Hepatology Research

View full text Add to dashboard Cite

Aim: Hepatocellular carcinoma (HCC) is a common malignancy associated with a poor prognosis due to difficulties in reliably estimating overall survival (OS). MicroRNAs (miRNAs) play critical roles in HCC initiation, progression, and metastasis and are highly correlated with patient prognosis. Thus, miRNA based risk signatures and nomograms are urgently required for predicting OS in patients with HCC. Methods: We constructed a 13 miRNA based signature and prognostic nomogram using 408 HCC samples and 58 normal tissues with miRNA sequencing data and clinical data from 323 patients downloaded from The Cancer Genome Atlas. A total of 195 patients were assigned as the internal validation cohort for verification and testing. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis was applied to investigate pathway enrichment for the signature. Results: We identified and validated a 13 miRNA risk signature highly associating with the OS of HCC patients. The signature showed good performances by calculating C index, area under the curve, and calibration curves. After verification and testing using an internal validation cohort, the results yielded a miRNA based signature and a prognostic nomogram with reliable predictive accuracy. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis indicated that various genes and multiple pathways were closely related to the mechanisms of HCC proliferation and metastasis. Conclusion: We successfully identified a 13 miRNA based signature and prognostic nomogram that are capable of predicting OS in patients with HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Construction of a 13‐microRNA‐based signature and prognostic nomogram for predicting overall survival in patients with hepatocellular carcinoma

Zheng

Wen

Nie

et al. 2020

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…Copyright © 2018 Royal Society of Chemistry. (D) The nucleobase head of GOA prodrug was proposed to bind to nucleobase of miRNAs with hydrogen-bond interaction, and the oleic acid tail chains could provide hydrophobic forces to self-assemble into GOA/miR nanoparticles in aqueous solution [ 86 ]. Reproduced with the permission from Ref.…”

Section: Synthetic Non-viral Vectors For Rna Deliverymentioning

confidence: 99%

“…Taking advantage of hydrogen bonding and hydrophobic interactions for loading RNAs, Wang et al [ 86 ] synthesized amphiphilic gemcitabine prodrug (GOA conjugate), and used the cytosine of gemcitabine to bind with miRNAs through hydrogen bond interaction of nucleobases. Then the GOA/miRNA complexes were further self-assembled into NPs with a hydrophobic interaction of tail chains.…”

Section: Synthetic Non-viral Vectors For Rna Deliverymentioning

confidence: 99%

Non-viral vectors for RNA delivery

Yan

Liu

et al. 2022

Journal of Controlled Release

Self Cite

186

100

View full text Add to dashboard Cite

RNA-based therapy is a promising and potential strategy for disease treatment by introducing exogenous nucleic acids such as messenger RNA (mRNA), small interfering RNA (siRNA), microRNA (miRNA) or antisense oligonucleotides (ASO) to modulate gene expression in specific cells. It is exciting that mRNA encoding the spike protein of COVID-19 (coronavirus disease 2019) delivered by lipid nanoparticles (LNPs) exhibits the efficient protection of lungs infection against the virus. In this review, we introduce the biological barriers to RNA delivery in vivo and discuss recent advances in non-viral delivery systems, such as lipid-based nanoparticles, polymeric nanoparticles, N -acetylgalactosamine (GalNAc)-siRNA conjugate, and biomimetic nanovectors, which can protect RNAs against degradation by ribonucleases, accumulate in specific tissue, facilitate cell internalization, and allow for the controlled release of the encapsulated therapeutics.

show abstract

“…However, the efficacy and biosafety for systemic administration remain major concerns that may delay the further clinical application. Zhang et al assembled amphiphilic gemcitabine‒oleic acid prodrugs (GOA) binding miRNAs with hydrogen bonds into nanoparticles to form GOA/miR nanoparticles [ 140 ]. They demonstrated that GOA/miR-122 nanoparticles accumulated significantly in tumors and inhibited tumor growth in vivo, without inducing significant inflammation or the alteration of biochemical indicators, indicating their efficacy and biosafety using negatively charged GOA/miR nanoparticles.…”

Section: Mirnas As Therapeutic Targets In Cholangiocarcinomamentioning

confidence: 99%

“…They demonstrated that GOA/miR-122 nanoparticles accumulated significantly in tumors and inhibited tumor growth in vivo, without inducing significant inflammation or the alteration of biochemical indicators, indicating their efficacy and biosafety using negatively charged GOA/miR nanoparticles. However, owing to the cancer model in this study being hepatocellular carcinoma [ 140 ], the function and biosafety of the noncationic GOA/miR nanoparticles in CCA warrant further research.…”

Section: Mirnas As Therapeutic Targets In Cholangiocarcinomamentioning

confidence: 99%

The Emerging Role of MicroRNAs in Regulating the Drug Response of Cholangiocarcinoma

Huang

Yeh

2020

Biomolecules

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is the most common biliary malignancy, and has a poor prognosis. The median overall survival with the standard-of-care chemotherapy (Gemcitabine and cisplatin) in patients with advanced-stage CCA is less than one year. The limited efficacy of chemotherapy or targeted therapy remains a major obstacle to improving survival. The mechanisms involved in drug resistance are complex. Research efforts focusing on the distinct molecular mechanisms underlying drug resistance should prompt the development of treatment strategies that overcome chemoresistance or targeted drug resistance. MicroRNAs (miRNAs) are a class of evolutionarily conserved, short noncoding RNAs regulating gene expression at the post-transcriptional level. Dysregulated miRNAs have been shown to participate in almost all CCA hallmarks, including cell proliferation, migration and invasion, apoptosis, and the epithelial-to-mesenchymal transition. Emerging evidence demonstrates that miRNAs play a role in regulating responses to chemotherapy and targeted therapy. Herein, we present an overview of the current knowledge on the miRNA-mediated regulatory mechanisms underlying drug resistance among CCA. We also discuss the application of miRNA-based therapeutics to CCA, providing the basis for innovative treatment approaches.

show abstract

Encapsulated microRNA by gemcitabine prodrug for cancer treatment

Cited by 21 publications

References 33 publications

Construction of a 13‐microRNA‐based signature and prognostic nomogram for predicting overall survival in patients with hepatocellular carcinoma

Construction of a 13‐microRNA‐based signature and prognostic nomogram for predicting overall survival in patients with hepatocellular carcinoma

Non-viral vectors for RNA delivery

The Emerging Role of MicroRNAs in Regulating the Drug Response of Cholangiocarcinoma

Contact Info

Product

Resources

About